Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. | Eli Lilly's latest high-profile crossovers—which include a starry TV partnership ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the ...

Maryland is becoming the home away from home for British drugmaker AstraZeneca. | Maryland is becoming the home away from ...

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Now, more than half a year later, the expansion plan for one of the company’s new facilities—a former magazine plant in ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by ...

After several notable moves to grow the reach of its biomanufacturing platform in recent months, Antheia is linking arms with ...

Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, ...